Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 2Phase 2 1

Status

Completed 4Terminated 2Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1INDIV 1

Study Type

Interventional 7

Sponsor

Cancer Type

Dermatologic 7

Conditions

Melanoma 7Leukemia, Myeloid, Acute 5Neoplasms 3Pathologic Complete Response 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2Multiple Myeloma 2Fallopian Tube Neoplasms 2Wilms Tumor 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Smoldering Multiple Myeloma 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasm, Residual 1Mesothelioma, Malignant 1Leukemia 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma 1Carcinogenesis 1Brain Neoplasms 1

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236Cyclophosphamide 135aldesleukin 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 68dabrafenib 65fludarabine phosphate 62sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35Magnetic Resonance Spectroscopy 33cobimetinib 32Specimen Handling 31Introns 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Interventional × Melanoma × Monatide (IMS 3015) × Clear all
NCT03929029 2026-01-05

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
11 enrolled 11 charts
Dermatologic

Melanoma

NCT01810016 2022-10-12

NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma

Ludwig Institute for Cancer Research

Phase 1 Terminated
8 enrolled 16 charts
Dermatologic

Melanoma, Neoplasms

NCT00112242 2020-06-18

Immunotherapy of Stage III/IV Melanoma Patients

Centre Hospitalier Universitaire Vaudois

Phase 1 Completed
39 enrolled 18 charts
Dermatologic

Melanoma

NCT01308294 2020-06-11

LAG-3/IMP321

Centre Hospitalier Universitaire Vaudois

Phase 1/2 Terminated
16 enrolled 12 charts
Dermatologic

Melanoma

NCT01079741 2018-02-13

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
34 enrolled 10 charts
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms, Carcinogenesis

NCT00124124 2015-02-13

Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine

Bhardwaj, Nina, M.D.

Phase 1 Completed
50 enrolled
Dermatologic

Melanoma

NCT00651703 2010-11-15

Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients

Cytos Biotechnology AG

Phase 2 Completed
21 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡